( November 5, 2026, 13:49 GMT | Official Statement) -- MLex Summary: Brazil’s competition authority, the Administrative Council for Economic Defense, or CADE, has recommended the approval of Novamed’s acquisition of Medley, a company owned by Sanofi, subject to a merger control agreement. The details of the proposal remain confidential, but CADE’s investigative arm, the Superintendence, noted that two markets raised concerns about the potential exercise of market power: gonadotropins and other ovulation stimulants; and selective serotonin receptor agonists used to treat migraines. A technical note concluded that the proposal submitted to CADE is timely and adequately addresses the identified competition concerns.Brazil’s Official Journal follows (in Portuguese). A technical note is attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.